Marinomed Biotech AG (MARI)

Currency in EUR
19.05
-0.90(-4.51%)
Closed·
MARI Scorecard
Full Analysis
Net income is expected to grow this year
MARI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
19.0519.10
52 wk Range
2.0021.00
Key Statistics
Bid/Ask
19.05 / 19.45
Prev. Close
19.95
Open
19.05
Day's Range
19.05-19.1
52 wk Range
2-21
Volume
150
Average Volume (3m)
1.21K
1-Year Change
232.5%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MARI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
46.00
Upside
+141.47%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

Marinomed Biotech AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Marinomed Biotech AG Company Profile

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company’s products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract. It also provides Solv4U which offers formulation development and biopharmaceutical testing services. It has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.

Employees
39
Market
Austria

Compare MARI to Peers and Sector

Metrics to compare
MARI
Peers
Sector
Relationship
P/E Ratio
−2.2x4.2x−0.5x
PEG Ratio
0.020.030.00
Price/Book
−1.3x0.7x2.6x
Price / LTM Sales
7.1x1.5x3.3x
Upside (Analyst Target)
141.5%99.7%40.6%
Fair Value Upside
Unlock1.8%5.3%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 46.00
(+141.47% Upside)

Earnings

Latest Release
May 27, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

MARI Income Statement

People Also Watch

788.73
META
+0.84%
230.73
AMZN
-0.11%
331.02
TSLA
-1.36%

FAQ

What Stock Exchange Does Marinomed Biotech AG Trade On?

Marinomed Biotech AG is listed and trades on the Vienna Stock Exchange stock exchange.

What Is the Stock Symbol for Marinomed Biotech AG?

The stock symbol for Marinomed Biotech AG is "MARI."

What Is the Marinomed Biotech AG Market Cap?

As of today, Marinomed Biotech AG market cap is 35.48M.

What Is Marinomed Biotech AG's Earnings Per Share (TTM)?

The Marinomed Biotech AG EPS (TTM) is -8.67.

When Is the Next Marinomed Biotech AG Earnings Date?

Marinomed Biotech AG will release its next earnings report on 16 Sept 2025.

From a Technical Analysis Perspective, Is MARI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Marinomed Biotech AG Stock Split?

Marinomed Biotech AG has split 0 times.

How Many Employees Does Marinomed Biotech AG Have?

Marinomed Biotech AG has 39 employees.

What is the current trading status of Marinomed Biotech AG (MARI)?

As of 15 Aug 2025, Marinomed Biotech AG (MARI) is trading at a price of 19.05, with a previous close of 19.95. The stock has fluctuated within a day range of 19.05 to 19.10, while its 52-week range spans from 2.00 to 21.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.